Other

Institut Pasteur De Lille

Institut National De La Sante Et De La Recherche Medicale

Universite Droit Et Sante Lille Ii

Nathalie Mielcarek

Camille Locht

Anne-Sophie Debrie

Dominique Raze

Julie Bertout

Gilles Riveau

Andr&eacute; Capron

Hana Kammoun

Odile Poulain-Godefroy

A mutatedstrain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutatedstrain can be used in an immunogenic composition or a vaccine for the treatment or prevention of ainfection. Use of the attenuatedstrain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection byare also provided.

Attenuatedstrains

Attenuated Bordetella strains

[object Object]

A genetically attenuatedstrain includes a mutated pertussis toxin (ptx) gene, and a heterologous ampG gene, and a hybrid protein including the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA. The strain can be used in an attenuated vaccine for the treatment or prophylaxis of an infectious disease.

Method of using attenuated bordetella strains

The invention concerns a Bordetella strain deficient in the production of toxin and expressing a hybrid protein comprising at least part of the filamentous hemagglutin (FHA) and at least part of a protein heterologous to FHA. The gene coding for the toxin has been eliminated, or at least partially deleted or mutated so as to produce an inactive toxin. This strain can be used as vaccine. The invention also concerns liposomes containing at least part of the FHA protein and at least one protein heterologous to the FHA protein, and the use of FHA for the stimulation of immune responses.

Bordetella strain expressing the FHA hybrid, liposomes and vaccines

Growing community of inventors

Blandain, Belgium

Nathalie Mielcarek